Bionano Genomics (NASDAQ: BNGO) awards 15,000 options to its general counsel
Rhea-AI Filing Summary
Bionano Genomics, Inc. reported that its General Counsel, Jonathan V. Dixon, received a grant of stock options for 15,000 shares of common stock on 2026-08-03. The options have an exercise price of $1.12 per share and expire on 2036-08-02. The award vests 50% on each of the first and second anniversaries of the vesting commencement date, subject to Continuous Service under the company’s 2018 Plan. Following this grant, Dixon holds options covering 15,000 shares. The company also states that this filing replaces an erroneously filed initial Form 3 dated August 5, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Dixon Jonathan V.
Role
General Counsel
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1, F2 | 15,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 15,000 shares (Direct)
Footnotes (2)
- F1. The shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each applicable vesting date.
- F2. The initial Form 3 filed on August 5, 2026 was erroneously filed. This Form 4 replaces the Form 3 filed.
Key Figures
Options granted: 15,000 options
Exercise price: $1.1200 per share
Expiration date: 2036-08-02
+2 more
5 metrics
Options granted
15,000 options
Stock option award to General Counsel on 2026-08-03
Exercise price
$1.1200 per share
Conversion or exercise price for the stock options
Expiration date
2036-08-02
Option expiration for the 15,000-share grant
Post-grant holdings
15,000 options
Total options held by Jonathan V. Dixon following this grant
Vesting per anniversary
50%
Portion of options vesting on each of first and second anniversaries
Key Terms
Stock Option (Right to Buy), Continuous Service, vesting commencement date, 2018 Plan
4 terms
Stock Option (Right to Buy) financial
"security_title is listed as Stock Option (Right to Buy) for this grant"
Continuous Service financial
"subject to the Reporting Person's Continuous Service through each applicable vesting date"
vesting commencement date financial
"on each of the first and second anniversaries of the vesting commencement date"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
2018 Plan financial
"as defined in the Company's 2018 Plan through each applicable vesting date"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Bionano Genomics (BNGO) report for Jonathan V. Dixon?
Bionano Genomics reported that General Counsel Jonathan V. Dixon received a grant of 15,000 stock options. The options relate to common stock, were granted on 2026-08-03, and give him the right to buy shares at a fixed exercise price if vesting conditions are met.
What are the key terms of the 15,000 stock options granted at Bionano Genomics (BNGO)?
The grant covers 15,000 stock options with an exercise price of $1.12 per share and an expiration date of 2036-08-02. These options allow purchase of an equal number of common shares once vested and exercised, subject to plan rules.
How do Jonathan V. Dixon’s BNGO options vest under this award?
The options vest in two equal installments of 50% each. Half vests on the first anniversary and the remaining half on the second anniversary of the vesting commencement date, contingent on his Continuous Service under the company’s 2018 Plan.
How many BNGO options does Jonathan V. Dixon hold after this transaction?
After this reported transaction, Jonathan V. Dixon holds options covering 15,000 shares of Bionano Genomics common stock. This reflects the full amount of the newly granted award, as disclosed in the post-transaction holdings field of the insider report.
Is the BNGO option grant to Jonathan V. Dixon part of a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not marked as affirmative. There is no footnote indicating a pre-arranged trading plan, suggesting this grant is standard equity compensation rather than a transaction executed under a 10b5-1 trading plan.